Oropharyngeal Squamous Cell Carcinoma (OPSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Oropharyngeal Squamous Cell Carcinoma (OPSCC) Market Outlook

Thelansis’s “Oropharyngeal Squamous Cell Carcinoma (OPSCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oropharyngeal Squamous Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Oropharyngeal Squamous Cell Carcinoma (OPSCC) Overview

Oropharyngeal cancer is a condition where cancerous cells develop in the tissues of the oropharynx, which constitutes the middle part of the pharynx. This area encompasses the tonsils, the back of the tongue, and the posterior throat walls. The pharynx serves as a passage for both air and food. Oropharyngeal cancers are commonly associated with HPV, and a positive HPV-16 polymerase chain reaction test of a biopsy or fine-needle aspiration is suggestive of oropharyngeal origin. Most oropharyngeal cancers are squamous cell carcinomas, thin, flat cells that line the interior of the oropharynx. Oropharyngeal cancer is relatively rare and typically afflicts individuals aged 50 to 80. The primary risk factors are smoking and excessive alcohol consumption. However, there has been a rise in cases among younger people infected with human papillomavirus (HPV). The signs and symptoms of oropharyngeal cancer can vary depending on the specific location, type, stage of cancer, and the individual genetic makeup of the tumor. These symptoms may include A lump in the neck or throat, Difficulty chewing or swallowing, along with pain, Sore throat, Unexplained ear pain, A persistent sore or ulcer lasting more than two weeks, Difficulty in mouth opening or tongue movement, A persistent white patch on the tongue or the lining of the mouth, Coughing up blood. Risk factors for oropharyngeal cancer can be attributed to environmental, behavioral, or genetic factors and include Tobacco use (cigarettes, pipes, cigars, chewing tobacco), Alcohol consumption, Exposure to human papillomavirus (HPV), including HPV type 16, A prior history of head and neck cancer.

• The global incidence of oropharyngeal squamous cell carcinoma (OPSCC) is estimated to range from approximately 95,000 to 112,000 new cases each year. Over the last few decades, the incidence of OPSCC has been on the rise due to an increase in cases of human papillomavirus-positive (HPV+) OPSCC.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: